

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity : BioProspect Limited
ABN: 58 008 130 336

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Peter Landau
Date of appointment	29 May 2007

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities 500,000 ordinary shares 500,000 options expiring 30 June 2007 @ \$0.05
--

Part 2 – Director’s relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest	Number & class of Securities
Susan Cann (spouse)	500,000 options expiring 30 June 2007 @ \$0.05

Part 3 – Director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	Lacka Consulting Pty Ltd
Nature of interest	Success fee for initiating the potential licence agreement with Solagran Limited which is subject to shareholder approval on 8 June 2007
Name of registered holder (if issued securities)	When issued will be to Lacka Consulting Pty Ltd
No. and class of securities to which interest relates	10,000,000 ordinary shares